Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 2, 2013, Pages 278-286

  Arcangeli, Sara ^a,b   Tozzi, Alessandro ^a,c   Tantucci, Michela ^a   Spaccatini, Cristiano ^a   De Iure, Antonio ^a   Costa, Cinzia ^a   Di Filippo, Massimiliano ^a   Picconi, Barbara ^c   Giampà, Carmen ^c   Fusco, Francesca Romana ^c   Amoroso, Salvatore ^b   Calabresi, Paolo ^a,c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

D1 dopamine receptor; in vitro ischemia; ischemic LTP; nitric oxide; NOS positive interneuron

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENOSINE A2A RECEPTOR; CYCLIC GMP; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; GUANYLATE CYCLASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; IMMUNOFLUORESCENCE TEST; INTERNEURON; ISCHEMIC LONG TERM POTENTIATION; LONG TERM POTENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD NERVE CELL; SYNAPTIC TRANSMISSION;

ANIMALS; BENZAZEPINES; BRAIN ISCHEMIA; CORPUS STRIATUM; CYCLIC GMP; GLUCOSE; GUANYLATE CYCLASE; INTERNEURONS; LONG-TERM POTENTIATION; MALE; NERVE TISSUE PROTEINS; NITRIC OXIDE; NITRIC OXIDE DONORS; OXYGEN; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D5; SYNAPTIC TRANSMISSION;

EID: 84873413896     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2012.167     Document Type: Article

References (55)

1. Hawker K, Lang AE. Hypoxic-ischemic damage of the basal ganglia. Case reports and a review of the literature. Mov Disord 1990; 5: 219-224.
2. Pulsinelli WA, Levy DE, Duffy TE. Regional cerebral blood flow and glucose metabolism following transient forebrain ischemia. Ann Neurol 1982; 11: 499-502.
3. White BC, Grossman LI, Krause GS. Brain injury by global ischemia and reperfusion: a theoretical perspective on membrane damage and repair. Neurology 1993; 43: 1656-1665.
4. Calabresi P, Saulle E, Marfia GA, Centonze D, Mulloy R, Picconi B et al. Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum. Mol Pharmacol 2001; 60: 808-815.
5. Calabresi P, Saulle E, Centonze D, Pisani A, Marfia GA, Bernardi G. Post-ischaemic long-term synaptic potentiation in the striatum: a putative mechanism for cell type-specific vulnerability. Brain 2002; 125: 844-860.
6. Calabresi P, Centonze D, Pisani A, Cupini L, Bernardi G. Synaptic plasticity in the ischaemic brain. Lancet Neurol 2003; 2: 622-629.
7. Di Filippo M, Tozzi A, Costa C, Belcastro V, Tantucci M, Picconi B et al. Plasticity and repair in the post-ischemic brain. Neuropharmacology 2008; 55: 353-362.
8. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391-397.
9. Moncada S, Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006; 97: 1676-1689.
10. Terpolilli NA, Moskowitz MA, Plesnila N. Nitric oxide: considerations for the treatment of ischemic stroke. J Cereb Blood Flow Metab 2012; 32: 1332-1346.
11. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265: 1883-1885.
12. Malenka RC, Nicoll RA. Long-term potentiation-a decade of progress? Science 1999; 285: 1870-1874.
13. Gallo EF, Iadecola C. Neuronal nitric oxide contributes to neuroplasticity-asso-ciated protein expression through cGMP, protein kinase G, and extracellular signal-regulated kinase. J Neurosci 2011; 31: 6947-6955.
14. Huang YC, Fisher PW, Nozik-Grayck E, Piantadosi CA. Hypoxia compared with normoxia alters the effects of nitric oxide in ischemia-reperfusion lung injury. Am J Physiol 1997; 273: L504-L512.
15. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615.
16. Garthwaite J. Concepts of neural nitric oxide-mediated transmission. Eur J Neu-rosci 2008; 27: 2783-2802.
17. Costa C, Tozzi A, Siliquini S, Galletti F, Cardaioli G, Tantucci M et al. A critical role of NO/cGMP/PKG dependent pathway in hippocampal post-ischemic LTP: modulation by zonisamide. Neurobiol Dis 2011; 44: 185-191.
18. Hopper RA, Garthwaite J. Tonic and phasic nitric oxide signals in hippocampal long-term potentiation. J Neurosci 2006; 26: 11513-11521.
19. Toner CC, Stamford JA. Characteristics of the NMDA receptor modulating hypoxia/hypoglycaemia-induced rat striatal dopamine release in vitro. Eur J Pharmacol 1997; 340: 133-143.
20. Furukawa N, Arai N, Goshima Y, Miyamae T, Ohshima E, Suzuki F et al. Endo-genously released DOPA is a causal factor for glutamate release and resultant delayed neuronal cell death by transient ischemia in rat striata. J Neurochem 2001; 76: 815-824.
21. Toner CC, Connelly K, Whelpton R, Bains S, Michael-Titus AT, McLaughlin DP et al. Effects of sevoflurane on dopamine, glutamate and aspartate release in an in vitro model of cerebral ischaemia. Br J Anaesth 2001; 86: 550-554.
22. Saulle E, Centonze D, Martin AB, Moratalla R, Bernardi G, Calabresi P. Endogenous dopamine amplifies ischemic long-term potentiation via D1 receptors. Stroke 2002; 33: 2978-2984.
23. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992; 15: 133-139.
24. Bolam JP, Hanley JJ, Booth PA, Bevan MD. Synaptic organisation of the basal ganglia. J Anat 2000; 196(Part 4): 527-542.
25. Bagetta V, Picconi B, Marinucci S, Sgobio C, Pendolino V, Ghiglieri V et al. Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. J Neurosci 2011; 31: 12513-12522.
26. Le Moine C, Normand E, Bloch B. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc Natl Acad Sci USA 1991; 88: 4205-4209.
27. Centonze D, Grande C, Usiello A, Gubellini P, Erbs E, Martin AB et al. Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci 2003; 23: 6245-6254.
28. Rivera A, Alberti I, Martin AB, Narvaez JA, de la Calle A, Moratalla R. Molecular phenotype of rat striatal neurons expressing the dopamine D5 receptor subtype. Eur J Neurosci 2002; 16: 2049-2058.
29. Sammut S, Dec A, Mitchell D, Linardakis J, Ortiguela M, West AR. Phasic dopa-minergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) receptor-dependent mechanism. Neuropsycho-pharmacology 2006; 31: 493-505.
30. Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007; 30: 211-219.
31. Bizzoco E, Vannucchi MG, Faussone-Pellegrini MS. Transient ischemia increases neuronal nitric oxide synthase, argininosuccinate synthetase and argi-ninosuccinate lyase co-expression in rat striatal neurons. Exp Neurol 2007; 204: 252-259.
32. Beckstead RM, Kersey KS. Immunohistochemical demonstration of differential substance P-, met-enkephalin-, and glutamic-acid-decarboxylase- containing cell body and axon distributions in the corpus striatum of the cat. J Comp Neurol 1985; 232: 481-498.
33. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999; 59: 355-396.
34. Rebola N, Rodrigues RJ, Lopes LV, Richardson PJ, Oliveira CR, Cunha RA. Adeno-sine A1 and A2A receptors are co-expressed in pyramidal neurons and co-localized in glutamatergic nerve terminals of the rat hippocampus. Neuroscience 2005; 133: 79-83.
35. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003; 6: 501-506.
36. Picconi B, Ghiglieri V, Bagetta V, Barone I, Sgobio C, Calabresi P. Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD. Parkinsonism Relat Disord 2008; 14(Suppl 2): S145-S149.
37. Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G. Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. Eur J Neurosci 1998; 10: 2887-2895.
38. Boulton CL, Southam E, Garthwaite J. Nitric oxide-dependent long-term poten-tiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Neuroscience 1995; 69: 699-703.
39. Altar CA, Boyar WC, Kim HS. Discriminatory roles for D1 and D2 dopamine receptor subtypes in the in vivo control of neostriatal cyclic GMP. Eur J Pharmacol 1990; 181: 17-21.
40. Isaev D, Ivanchick G, Khmyz V, Isaeva E, Savrasova A, Krishtal O et al. Surface charge impact in low-magnesium model of seizure in rat hippocampus. J Neu-rophysiol 2012; 107: 417-423.
41. Calabresi P, Misgeld U, Dodt HU. Intrinsic membrane properties of neostriatal neurons can account for their low level of spontaneous activity. Neuroscience 1987; 20: 293-303.
42. Iadecola C, Kahles T, Gallo EF, Anrather J. Neurovascular protection by ischaemic tolerance: role of nitric oxide. J Physiol 2011; 589: 4137-4145.
43. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 1997; 20: 132-139.
44. Buisson A, Plotkine M, Boulu RG. The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischaemia. Br J Pharmacol 1992; 106: 766-767.
45. Kovacs R, Rabanus A, Otahal J, Patzak A, Kardos J, Albus K et al. Endogenous nitric oxide is a key promoting factor for initiation of seizure-like events in hippocampal and entorhinal cortex slices. J Neurosci 2009; 29: 8565-8577.
46. Fedele E, Raiteri M. In vivo studies of the cerebral glutamate receptor/NO/cGMP pathway. Prog Neurobiol 1999; 58: 89-120.
47. Toner CC, Stamford JA. 'Real time' measurement of dopamine release in an in vitro model of neostriatal ischaemia. J Neurosci Methods 1996; 67: 133-140.
48. West AR, Tseng KY. Nitric oxide-soluble guanylyl cyclase-cyclic GMP signaling in the striatum: new targets for the treatment of Parkinson's disease? Front Syst Neurosci 2011; 5: 55.
49. Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999; 23: 435-447.
50. West AR, Grace AA. The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity States and electrophysiological properties of striatal medium spiny neurons recorded in vivo. J Neurosci 2004; 24: 1924-1935.
51. Ariano MA, Ufkes SK. Cyclic nucleotide distribution within rat striatonigral neurons. Neuroscience 1983; 9: 23-29.
52. de Vente J, Markerink-van Ittersum M, van Abeelen J, Emson PC, Axer H, Steinbusch HW. NO-mediated cGMP synthesis in cholinergic neurons in the rat forebrain: effects of lesioning dopaminergic or serotonergic pathways on nNOS and cGMP synthesis. Eur J Neurosci 2000; 12: 507-519.
53. Sancesario G, Giorgi M, D'Angelo V, Modica A, Martorana A, Morello M et al. Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur J Neurosci 2004; 20: 989-1000.
54. Bockelmann R, Wolf G, Ransmayr G, Riederer P. NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J Neural Transm Park Dis Dement Sect 1994; 7: 115-121.
55. Eve DJ, Nisbet AP, Kingsbury AE, Hewson EL, Daniel SE, Lees AJ et al. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res Mol Brain Res 1998; 63: 62-71.